CTLA4 and melanoma: Our group recently demonstrated that the high levels of CD28 and PD-1 exposed by Exo correlate with the therapeutic response to anti-CTLA4 immunotherapy in metastatic melanoma, whereas those from DCs reflect the restoration of immune system activity against melanoma cells [24].